Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study.

Suey-Haur LeeYu-Ching LinLi-Chung ChiuJia-Shiuan JuPi-Hung TungAllen Chung-Cheng HuangShih-Hong LiYueh-Fu FangChih-Hung ChenAllen Chung-Cheng HuangChin-Chou WangCheng-Ta YangPing-Chih Hsu

Published in: Therapeutic advances in medical oncology (2022)

Afatinib combined with bevacizumab was equally as effective as erlotinib combined with bevacizumab for untreated advanced EGFR-mutated NSCLC. Prospective clinical studies that explore bevacizumab combined with afatinib or erlotinib for advanced EGFR-mutated NSCLC are warranted.

Keyphrases

epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
small cell lung cancer
metastatic colorectal cancer
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
wild type